{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:53:29Z","timestamp":1777600409629,"version":"3.51.4"},"reference-count":44,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2010\/R\/12-2011\/R\/11"],"award-info":[{"award-number":["2010\/R\/12-2011\/R\/11"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 10237"],"award-info":[{"award-number":["IG 10237"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.00321","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:22:41Z","timestamp":1490228561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis"],"prefix":"10.3389","volume":"8","author":[{"given":"Nausicaa","family":"Clemente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristoforo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Raineri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cappellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domizia","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Orilieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casimiro L.","family":"Gigliotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Boggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Dianzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Sorosina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Martinelli-Boneschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Caldano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Ambrogio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Sblattero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Cena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Leone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Dianzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Chiocchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"issue":"3","key":"B1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.autrev.2011.05.008","article-title":"Immune-mediated CNS diseases: a review on nosological classification and clinical features","volume":"11","author":"Zettl","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"B2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0733-8619(18)30064-1","article-title":"The natural history of multiple sclerosis","volume":"13","author":"Weinshenker","year":"1995","journal-title":"Neurol Clin"},{"issue":"6","key":"B3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40291-014-0117-0","article-title":"Biomarkers of therapeutic response in multiple sclerosis: current status","volume":"18","author":"Harris","year":"2014","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"B4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/JAD-2011-102151","article-title":"The role of osteopontin in neurodegenerative diseases","volume":"25","author":"Carecchio","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"B5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JAD-2011-102151","article-title":"Osteopontin: a bridge between bone and the immune system","volume":"112","author":"Gravallese","year":"2003","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"B6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jneuroim.2005.02.020","article-title":"Osteopontin gene haplotypes correlate with multiple sclerosis development and progression","volume":"163","author":"Chiocchetti","year":"2005","journal-title":"J Neuroimmunol"},{"issue":"4","key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/03009740801910320","article-title":"Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate","volume":"37","author":"Sennels","year":"2008","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"B8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/art.20808","article-title":"Two single-nucleotide polymorphisms in the 5\u2019 and 3\u2019 ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus","volume":"52","author":"D\u2019Alfonso","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"B9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/MCG.0b013e31802d6268","article-title":"High plasma osteopontin levels in patients with inflammatory bowel disease","volume":"41","author":"Mishima","year":"2007","journal-title":"J Clin Gastroenterol"},{"issue":"5547","key":"B10","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1126\/science.1062960","article-title":"The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease","volume":"294","author":"Chabas","year":"2001","journal-title":"Science"},{"issue":"4","key":"B11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2174\/187152810793358778","article-title":"The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS)","volume":"9","author":"Braitch","year":"2010","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"1\u20132","key":"B12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jneuroim.2004.09.004","article-title":"Plasma osteopontin levels in multiple sclerosis","volume":"158","author":"Comabella","year":"2005","journal-title":"J Neuroimmunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"212893","DOI":"10.1155\/2012\/212893","article-title":"The impact of osteopontin gene variations on multiple sclerosis development and progression","volume":"2012","author":"Comi","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"51","key":"B14","doi-asserted-by":"publisher","first-page":"36328","DOI":"10.1074\/jbc.274.51.36328","article-title":"The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin","volume":"274","author":"Yokosaki","year":"1999","journal-title":"J Biol Chem"},{"issue":"11","key":"B15","doi-asserted-by":"publisher","first-page":"7480","DOI":"10.4049\/jimmunol.181.11.7480","article-title":"Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis","volume":"181","author":"Murugaiyan","year":"2008","journal-title":"J Immunol"},{"issue":"3","key":"B16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/ajh\/hps043","article-title":"N-terminal rather than full-length osteopontin orits C-terminal fragment is associated with carotid-plaque inflammation inhypertensive patients","volume":"26","author":"Wolak","year":"2013","journal-title":"Am J Hypertens"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9345495","DOI":"10.1155\/2016\/9345495","article-title":"Thrombin cleavage of osteopontin modulates its activities in human cells in vitro and mouse experimental autoimmune encephalomyelitis in vivo","volume":"2016","author":"Boggio","year":"2016","journal-title":"J Immunol Res"},{"issue":"1","key":"B18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ni1415","article-title":"Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells","volume":"8","author":"Hur","year":"2007","journal-title":"Nat Immunol"},{"issue":"5614","key":"B19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1126\/science.1080223","article-title":"Response to comment on \u201cthe influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease\u201d","volume":"299","author":"Steinman","year":"2003","journal-title":"Science"},{"issue":"7","key":"B20","first-page":"1492","article-title":"Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis","volume":"28","author":"Sakata","year":"2001","journal-title":"J Rheumatol"},{"issue":"7","key":"B21","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/art.23490","article-title":"Treatment of collagen-induced arthritis with ananti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells","volume":"58","author":"Fan","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"B22","first-page":"136","article-title":"Anti-cytokine autoantibodies in autoimmune diseases","volume":"1","author":"Cappellano","year":"2012","journal-title":"Am J Clin Exp Immunol"},{"issue":"1","key":"B23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"issue":"4","key":"B24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/1352458507084650","article-title":"Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study","volume":"14","author":"Leone","year":"2008","journal-title":"Mult Scler"},{"issue":"7","key":"B25","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple sclerosis severity score: using disability and disease duration torate disease severity","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology"},{"issue":"11","key":"B26","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/eji.200636662","article-title":"Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis","volume":"36","author":"Uyttenhove","year":"2006","journal-title":"Eur J Immunol"},{"issue":"43","key":"B27","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1016\/j.vaccine.2014.08.016","article-title":"Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis","volume":"32","author":"Cappellano","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"B28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/71958","article-title":"Exploiting recombination in single bacteria to make large phage antibody libraries","volume":"18","author":"Sblattero","year":"2000","journal-title":"Nat Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1472-6750-7-46","article-title":"Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models","volume":"7","author":"Di Niro","year":"2007","journal-title":"BMC Biotechnol"},{"issue":"7","key":"B30","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.autrev.2016.03.006","article-title":"Therapeutic strategies targeting B-cells in multiple sclerosis","volume":"15","author":"Milo","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"4","key":"B31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1\u20132","key":"B32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jns.2015.02.019","article-title":"ATON: results from a phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis","volume":"351","author":"Sergott","year":"2015","journal-title":"J Neurol Sci"},{"issue":"4","key":"B33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/0091270008315312","article-title":"Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis","volume":"48","author":"Nestorov","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbi.2013.08.009","article-title":"The improvement of cognitive functions is associated with a decrease of plasma osteopontin levels in natalizumab treated relapsing multiple sclerosis","volume":"35","author":"Iaffaldano","year":"2014","journal-title":"Brain Behav Immun"},{"issue":"1\u20132","key":"B35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2013.07.005","article-title":"Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica","volume":"263","author":"Shimizu","year":"2013","journal-title":"J Neuroimmunol"},{"issue":"4","key":"B36","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1177\/1352458513503052","article-title":"Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development","volume":"20","author":"Kivis\u00e4kk","year":"2014","journal-title":"Mult Scler"},{"issue":"12","key":"B37","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1177\/1352458514528765","article-title":"No evidence for an association of osteopontin plasma levels with disease activity in multiple sclerosis","volume":"20","author":"Runia","year":"2014","journal-title":"Mult Scler"},{"issue":"12","key":"B38","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.4049\/jimmunol.1004043","article-title":"CD44 reciprocally regulates the differentiation of encephalitogenic Th1\/Th17 and Th2\/regulatory T cells through epigenetic modulation involving DNA methylation of cytokine gene promoters, thereby controlling the development of experimental autoimmune encephalomyelitis","volume":"186","author":"Guan","year":"2011","journal-title":"J Immunol"},{"issue":"40","key":"B39","doi-asserted-by":"publisher","first-page":"33237","DOI":"10.1074\/jbc.M112.356287","article-title":"Hyaluronan anchored to activated CD44 on central nervous system vascular endothelial cells promotes lymphocyte extravasation in experimental autoimmune encephalomyelitis","volume":"287","author":"Winkler","year":"2012","journal-title":"J Biol Chem"},{"issue":"4","key":"B40","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.ajpath.2013.01.003","article-title":"CD44 deficiency contributes to enhanced experimental autoimmune encephalomyelitis: a role in immune cells and vascular cells of the blood-brain barrier","volume":"182","author":"Flynn","year":"2013","journal-title":"Am J Pathol"},{"issue":"2","key":"B41","doi-asserted-by":"publisher","first-page":"e57430","DOI":"10.1371\/journal.pone.0057430","article-title":"Overexpression of CD44 in neural precursor cells improves trans-endothelial migration and facilitates their invasion of perivascular tissues in vivo","volume":"8","author":"Deboux","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"B42","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1096\/fj.13-228809","article-title":"CD44 variant isoforms control experimental autoimmune encephalomyelitis by affecting the lifespan of the pathogenic T cells","volume":"27","author":"Ghazi-Visser","year":"2013","journal-title":"FASEB J"},{"issue":"2","key":"B43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.autrev.2011.08.011","article-title":"The role of T cell apoptosis in nervous system autoimmunity","volume":"12","author":"Comi","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"5\u20136","key":"B44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cytogfr.2008.08.001","article-title":"Osteopontin: role in immune regulation and stress responses","volume":"19","author":"Wang","year":"2008","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00321\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T22:56:48Z","timestamp":1568933808000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00321\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":44,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.00321","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,23]]}}}